Role of Traditional Cardiovascular Risk Factors after Initiation of Statin Therapy: A PharmLines Inception Cohort Study
Background. Multiple studies and meta-analyses examined the role of traditional risk factors for cardiovascular events in statin treatment-naive patients. Nowadays, millions receive such therapy for the primary prevention of cardiovascular events (CVE). Objective. CVEs still occur in patients on pri...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Cardiovascular Therapeutics |
| Online Access: | http://dx.doi.org/10.1155/2022/6587165 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565427325108224 |
|---|---|
| author | Dennis Steenhuis Stijn de Vos Jens Bos Eelko Hak |
| author_facet | Dennis Steenhuis Stijn de Vos Jens Bos Eelko Hak |
| author_sort | Dennis Steenhuis |
| collection | DOAJ |
| description | Background. Multiple studies and meta-analyses examined the role of traditional risk factors for cardiovascular events in statin treatment-naive patients. Nowadays, millions receive such therapy for the primary prevention of cardiovascular events (CVE). Objective. CVEs still occur in patients on primary preventive statin therapy. Therefore, further risk stratification within these patients is urgently needed. Methods. Using the unique linkage between biomedical data and prescription data from the PharmLines Initiative, we assessed the role of several risk factors used in cardiovascular risk models, using a time-dependent Cox PH model, in the occurrence of drug treatment of CVEs after initiation of statin therapy. Results. Among 602 statin therapy starters, 11% received drug treatment for CVE within an average follow-up period of 832 days. After multivariable modelling, cholesterol levels and blood pressure at baseline were no longer associated, whereas self-reported diabetes and increasing age were highly associated with the outcome when on statin therapy (hazard ratio (HR): 3.01, 95% confidence interval (95% CI): 1.48-6.12 and 1.04; 95% CI: 1.01-1.07, respectively). Males, smokers, and nonadherent patients had increased risks (HR 1.6, 1.12, and 1.18, resp.), though not statistically significant. Conclusion. Drug treatment for CVEs after statin initiation is increased in patients with diabetes type 2, in aged patients, males, smokers, and those with poor adherence, while there was no association with baseline cholesterol levels and blood pressure. These factors should be taken into account during the monitoring of statin therapy and may lead to changes in statin treatment or risk-related lifestyle factors. |
| format | Article |
| id | doaj-art-23fe4519095f4afdaddb65f49b59c72b |
| institution | Kabale University |
| issn | 1755-5922 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiovascular Therapeutics |
| spelling | doaj-art-23fe4519095f4afdaddb65f49b59c72b2025-02-03T01:07:36ZengWileyCardiovascular Therapeutics1755-59222022-01-01202210.1155/2022/6587165Role of Traditional Cardiovascular Risk Factors after Initiation of Statin Therapy: A PharmLines Inception Cohort StudyDennis Steenhuis0Stijn de Vos1Jens Bos2Eelko Hak3Department of PharmacotherapyDepartment of PharmacotherapyDepartment of PharmacotherapyDepartment of PharmacotherapyBackground. Multiple studies and meta-analyses examined the role of traditional risk factors for cardiovascular events in statin treatment-naive patients. Nowadays, millions receive such therapy for the primary prevention of cardiovascular events (CVE). Objective. CVEs still occur in patients on primary preventive statin therapy. Therefore, further risk stratification within these patients is urgently needed. Methods. Using the unique linkage between biomedical data and prescription data from the PharmLines Initiative, we assessed the role of several risk factors used in cardiovascular risk models, using a time-dependent Cox PH model, in the occurrence of drug treatment of CVEs after initiation of statin therapy. Results. Among 602 statin therapy starters, 11% received drug treatment for CVE within an average follow-up period of 832 days. After multivariable modelling, cholesterol levels and blood pressure at baseline were no longer associated, whereas self-reported diabetes and increasing age were highly associated with the outcome when on statin therapy (hazard ratio (HR): 3.01, 95% confidence interval (95% CI): 1.48-6.12 and 1.04; 95% CI: 1.01-1.07, respectively). Males, smokers, and nonadherent patients had increased risks (HR 1.6, 1.12, and 1.18, resp.), though not statistically significant. Conclusion. Drug treatment for CVEs after statin initiation is increased in patients with diabetes type 2, in aged patients, males, smokers, and those with poor adherence, while there was no association with baseline cholesterol levels and blood pressure. These factors should be taken into account during the monitoring of statin therapy and may lead to changes in statin treatment or risk-related lifestyle factors.http://dx.doi.org/10.1155/2022/6587165 |
| spellingShingle | Dennis Steenhuis Stijn de Vos Jens Bos Eelko Hak Role of Traditional Cardiovascular Risk Factors after Initiation of Statin Therapy: A PharmLines Inception Cohort Study Cardiovascular Therapeutics |
| title | Role of Traditional Cardiovascular Risk Factors after Initiation of Statin Therapy: A PharmLines Inception Cohort Study |
| title_full | Role of Traditional Cardiovascular Risk Factors after Initiation of Statin Therapy: A PharmLines Inception Cohort Study |
| title_fullStr | Role of Traditional Cardiovascular Risk Factors after Initiation of Statin Therapy: A PharmLines Inception Cohort Study |
| title_full_unstemmed | Role of Traditional Cardiovascular Risk Factors after Initiation of Statin Therapy: A PharmLines Inception Cohort Study |
| title_short | Role of Traditional Cardiovascular Risk Factors after Initiation of Statin Therapy: A PharmLines Inception Cohort Study |
| title_sort | role of traditional cardiovascular risk factors after initiation of statin therapy a pharmlines inception cohort study |
| url | http://dx.doi.org/10.1155/2022/6587165 |
| work_keys_str_mv | AT dennissteenhuis roleoftraditionalcardiovascularriskfactorsafterinitiationofstatintherapyapharmlinesinceptioncohortstudy AT stijndevos roleoftraditionalcardiovascularriskfactorsafterinitiationofstatintherapyapharmlinesinceptioncohortstudy AT jensbos roleoftraditionalcardiovascularriskfactorsafterinitiationofstatintherapyapharmlinesinceptioncohortstudy AT eelkohak roleoftraditionalcardiovascularriskfactorsafterinitiationofstatintherapyapharmlinesinceptioncohortstudy |